Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4IABG)

Drug Name

PMID17480064C16 Drug Info

Synonyms

724711-21-1; 3fhr; 2jbp; 2jbo; P4O; Pyrrolopyridine, 16; Kinome_3179; 3r2y; GTPL8177; BDBM30185; ZINC16052855; AKOS027322581; DB08358; KB-19275; DB-013997; FT-0745988

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10389239
TTD Drug ID: DM4IABG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting MAPK-activated protein kinase 2 (MAPKAPK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zunsemetinib	DMNFNK7	Cryopyrin-associated periodic syndrome	4A60.1	Phase 2	[2]
CBP-501	DMCWVPU	Mesothelioma	2C51.2	Phase 1/2	[3]
MMI-0100	DMIMVEX	Airway inflammation	CA05	Phase 1	[4]
PMID19364658C33	DMSE1C3	Discovery agent	N.A.	Investigative	[5]
PF-3644022	DM6KVIA	Discovery agent	N.A.	Investigative	[6]
CMPD1	DMKNUYF	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting MAPK-activated protein kinase 5 (MAPKAPK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLPG-0259	DMC87DR	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MAPK-activated protein kinase 2 (MAPKAPK2)	TTMUG9D	MAPK2_HUMAN	Inhibitor	[1]
MAPK-activated protein kinase 3 (MAPKAPK3)	TTFS4VU	MAPK3_HUMAN	Inhibitor	[1]
MAPK-activated protein kinase 5 (MAPKAPK5)	TT3UJ7Z	MAPK5_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
2	Clinical pipeline report, company report or official report of Aclaris Therapeutics
3	National Cancer Institute Drug Dictionary (drug id 577812).
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094).
5	Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
6	A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807.
7	Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2096).